{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:52:03Z","timestamp":1791899523777,"version":"4.3.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:00:00Z","timestamp":1601078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:00:00Z","timestamp":1601078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00018-020-03652-2","type":"journal-article","created":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T14:03:38Z","timestamp":1601129018000},"page":"1191-1206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4497-4427","authenticated-orcid":false,"given":"Sedigheh","family":"Taghinezhad-S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7525-3131","authenticated-orcid":false,"given":"Luis G.","family":"Berm\u00fadez-Humar\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert G. G.","family":"Donders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangsheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0320-9523","authenticated-orcid":false,"given":"Amir Hossein","family":"Mohseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,26]]},"reference":[{"issue":"1","key":"3652_CR1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1741-7015-10-72","volume":"10","author":"M-K Cha","year":"2012","unstructured":"Cha M-K, Lee D-K, An H-M, Lee S-W, Shin S-H, Kwon J-H, Kim K-J, Ha N-J (2012) Antiviral activity of Bifidobacterium adolescentisSPM1005-A on human papillomavirus type 16. BMC Med 10(1):72","journal-title":"BMC Med"},{"issue":"11","key":"3652_CR2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1469-0691.2009.03032.x","volume":"15","author":"E Galani","year":"2009","unstructured":"Galani E, Christodoulou C (2009) Human papilloma viruses and cancer in the post-vaccine era. Clin Microbiol Infect 15(11):977\u2013981","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"3652_CR3","doi-asserted-by":"crossref","first-page":"020","DOI":"10.1186\/s12885-020-06946-7","volume":"20","author":"MT Bruno","year":"2020","unstructured":"Bruno MT, Scalia G, Cassaro N, Boemi S (2020) Multiple HPV 16 infection with two strains: a possible marker of neoplastic progression. BMC Cancer 20(1):020\u201306946","journal-title":"BMC Cancer"},{"key":"3652_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/B978-0-12-814457-2.00009-X","volume-title":"Human papillomavirus","author":"A-B Moscicki","year":"2020","unstructured":"Moscicki A-B, Schiffman M, Franceschi S (2020) Chapter 9\u2014the natural history of human papillomavirus infection in relation to cervical cancer. In: Jenkins D, Bosch FX (eds) Human papillomavirus. Academic Press, New York, pp 149\u2013160. https:\/\/doi.org\/10.1016\/B978-0-12-814457-2.00009-X"},{"key":"3652_CR5","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.vaccine.2006.05.110","volume":"24","author":"M Stanley","year":"2006","unstructured":"Stanley M, Lowy DR, Frazer I (2006) Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24:S106\u2013S113","journal-title":"Vaccine"},{"issue":"9","key":"3652_CR6","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4014\/jmb.1906.06021","volume":"29","author":"E Kim","year":"2019","unstructured":"Kim E, Yang J, Sung M-H, Poo H (2019) Oral Administration of poly-gamma-glutamic acid significantly enhances the antitumor effect of HPV16 E7-expressing Lactobacillus casei in a TC-1 mouse model. J Microbiol Biotechnol 29(9):1444\u20131452","journal-title":"J Microbiol Biotechnol"},{"issue":"3","key":"3652_CR7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00253-012-4575-1","volume":"97","author":"P Ribelles","year":"2013","unstructured":"Ribelles P, Benbouziane B, Langella P, Su\u00e1rez JE, Berm\u00fadez-Humar\u00e1n LG, Riazi A (2013) Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Appl Microbiol Biotechnol 97(3):1231\u20131239","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"3652_CR8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0929-6646(10)60017-4","volume":"109","author":"K Lin","year":"2010","unstructured":"Lin K, Doolan K, Hung C-F, Wu TC (2010) Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 109(1):4\u201324","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"3652_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2010.00970.x","volume":"239","author":"MF Pasetti","year":"2011","unstructured":"Pasetti MF, Simon JK, Sztein MB, Levine MM (2011) Immunology of gut mucosal vaccines. Immunol Rev 239(1):125\u2013148","journal-title":"Immunol Rev"},{"issue":"4","key":"3652_CR10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s12602-017-9320-8","volume":"10","author":"AH Mohseni","year":"2018","unstructured":"Mohseni AH, Taghinezhad SS, Keyvani H, Ghobadi N (2018) Comparison of acyclovir and multistrain Lactobacillus brevis in women with recurrent genital herpes infections: a double-blind, randomized, Controlled Study. Probiotics Antimicrob Proteins 10(4):740\u2013747","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"1","key":"3652_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1525-1438.2001.011001009.x","volume":"11","author":"M Tjiong","year":"2001","unstructured":"Tjiong M, Out T, Ter Schegget J, Burger M, Van Der Vange N (2001) Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review. Int J Gynecol Cancer 11(1):9\u201317","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"3652_CR12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","volume":"6","author":"MR Neutra","year":"2006","unstructured":"Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6(2):148\u2013158","journal-title":"Nat Rev Immunol"},{"issue":"13\u201314","key":"3652_CR13","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0264-410X(00)00354-6","volume":"19","author":"E Medina","year":"2001","unstructured":"Medina E, Guzm\u00e1n CA (2001) Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19(13\u201314):1573\u20131580","journal-title":"Vaccine"},{"key":"3652_CR14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fmicb.2017.00800","volume":"8","author":"RDO Carvalho","year":"2017","unstructured":"Carvalho RDO, do Carmo FLR, de Oliveirajunior A, Langella P, Chatel JM, Berm\u00fadez-Humar\u00e1n LG, Azevedo V, de Azevedo MS (2017) Use of wild type or recombinant lactic acid bacteria as an alternative treatment for gastrointestinal inflammatory diseases: a focus on inflammatory bowel diseases and mucositis. Front Microbiol 8:800","journal-title":"Front Microbiol"},{"issue":"13","key":"3652_CR15","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1007\/s00253-016-7557-x","volume":"100","author":"M Wang","year":"2016","unstructured":"Wang M, Gao Z, Zhang Y, Pan L (2016) Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option. Appl Microbiol Biotechnol 100(13):5691\u20135701","journal-title":"Appl Microbiol Biotechnol"},{"issue":"3","key":"3652_CR16","first-page":"783","volume":"18","author":"AH Mohseni","year":"2017","unstructured":"Mohseni AH, Razavilar V, Keyvani H, Razavi MR, Khavari Nejad RA (2017) Codon usage optimization and construction of plasmid encoding iranian human papillomavirus type 16 E7 oncogene for Lactococcus Lactis Subsp. cremoris MG1363. Asian Pac J Cancer Prev 18(3):783\u2013788","journal-title":"Asian Pac J Cancer Prev"},{"key":"3652_CR17","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.3389\/fmicb.2018.03179","volume":"9","author":"B del Rio","year":"2019","unstructured":"del Rio B, Redruello B, Fernandez M, Martin MC, Ladero V, Alvarez MA (2019) Lactic acid bacteria as a live delivery system for the in situ production of nanobodies in the human gastrointestinal tract. Front Microbiol 9:3179. https:\/\/doi.org\/10.3389\/fmicb.2018.03179","journal-title":"Front Microbiol"},{"issue":"4","key":"3652_CR18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1472-765X.2010.02905.x","volume":"51","author":"D Quisti\u00e1n-Mart\u00ednez","year":"2010","unstructured":"Quisti\u00e1n-Mart\u00ednez D, Villatoro-Hern\u00e1ndez J, Loera-Arias MJ, Rangel-Colmenero BR, Zavala-Flores LM, Sep\u00falveda-Saavedra J, Guzm\u00e1n-L\u00f3pez S, Elizondo-Oma\u00f1a RE, Montes-de-Oca-Luna R, Saucedo-C\u00e1rdenas O (2010) Efficient secretion of a modified E7 protein from human papilloma virus type-16 by Lactococcus lactis. Lett Appl Microbiol 51(4):383\u2013387","journal-title":"Lett Appl Microbiol"},{"issue":"15","key":"3652_CR19","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1007\/s00253-019-09912-x","volume":"103","author":"K Takahashi","year":"2019","unstructured":"Takahashi K, Orito N, Tokunoh N, Inoue N (2019) Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers. Appl Microbiol Biotechnol 103(15):5947\u20135955","journal-title":"Appl Microbiol Biotechnol"},{"key":"3652_CR20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.micpath.2018.10.043","volume":"126","author":"SS Taghinezhad","year":"2019","unstructured":"Taghinezhad SS, Mohseni AH, Keyvani H, Razavilar V (2019) Protection against human papillomavirus type 16-induced tumors in C57BL\/6 mice by mucosal vaccination with Lactococcus lactis NZ9000 expressing E6 oncoprotein. Microb Pathog 126:149\u2013156","journal-title":"Microb Pathog"},{"issue":"10","key":"3652_CR21","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1080\/21645515.2017.1346755","volume":"13","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Zhang J, Xia N, Zhao Q (2017) Expanded strain coverage for a highly successful public health tool: prophylactic 9-valent human papillomavirus vaccine. Hum Vaccin Immunother 13(10):2280\u20132291","journal-title":"Hum Vaccin Immunother"},{"issue":"10 Suppl","key":"3652_CR22","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/cncr.23763","volume":"113","author":"EF Dunne","year":"2008","unstructured":"Dunne EF, Datta SD, Markowitz EL (2008) A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Cancer 113(10 Suppl):2995\u20133003","journal-title":"Cancer"},{"issue":"1","key":"3652_CR23","doi-asserted-by":"crossref","first-page":"e0169533","DOI":"10.1371\/journal.pone.0169533","volume":"12","author":"B Huber","year":"2017","unstructured":"Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R (2017) Chimeric L2-based virus-like particle (VLP) vaccines targeting cutaneous human papillomaviruses (HPV). PLoS ONE 12(1):e0169533","journal-title":"PLoS ONE"},{"issue":"9","key":"3652_CR24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0167-7799(03)00190-2","volume":"21","author":"MK Dyck","year":"2003","unstructured":"Dyck MK, Lacroix D, Pothier F, Sirard M-A (2003) Making recombinant proteins in animals\u2013different systems, different applications. Trends Biotechnol 21(9):394\u2013399","journal-title":"Trends Biotechnol"},{"issue":"47","key":"3652_CR25","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2007.09.024","volume":"25","author":"HJ Cho","year":"2007","unstructured":"Cho HJ, Shin HJ, Han IK, Jung WW, Kim YB, Sul D, Oh YK (2007) Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine 25(47):8049\u20138057","journal-title":"Vaccine"},{"issue":"2","key":"3652_CR26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/viro.1998.9050","volume":"243","author":"W Zhang","year":"1998","unstructured":"Zhang W, Carmichael J, Ferguson J, Inglis S, Ashrafian H, Stanley M (1998) Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro. Virology 243(2):423\u2013431","journal-title":"Virology"},{"issue":"1","key":"3652_CR27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1128\/AEM.72.1.745-752.2006","volume":"72","author":"KA Aires","year":"2006","unstructured":"Aires KA, Cianciarullo AM, Carneiro SM, Villa LL, Boccardo E, P\u00e9rez-Martinez G, Perez-Arellano I, Oliveira ML, Ho PL (2006) Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol 72(1):745\u2013752","journal-title":"Appl Environ Microbiol"},{"issue":"167","key":"3652_CR28","first-page":"1756","volume":"2","author":"NG Cortes-Perez","year":"2009","unstructured":"Cortes-Perez NG, Kharrat P, Langella P, Berm\u00fadez-Humar\u00e1n LG (2009) Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium. BMC Res Notes 2(167):1756\u20132500","journal-title":"BMC Res Notes"},{"issue":"21","key":"3652_CR29","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1128\/JVI.01577-07","volume":"81","author":"R Gambhira","year":"2007","unstructured":"Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB (2007) Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 81(21):11585\u201311592","journal-title":"J Virol"},{"issue":"22","key":"3652_CR30","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2012.03.009","volume":"30","author":"S-W Yoon","year":"2012","unstructured":"Yoon S-W, Lee T-Y, Kim S-J, Lee I-H, Sung M-H, Park J-S, Poo H (2012) Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb\/c mice. Vaccine 30(22):3286\u20133294","journal-title":"Vaccine"},{"issue":"11","key":"3652_CR31","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.4049\/jimmunol.175.11.7297","volume":"175","author":"LG Berm\u00fadez-Humar\u00e1n","year":"2005","unstructured":"Berm\u00fadez-Humar\u00e1n LG, Cortes-Perez NG, Lef\u00e8vre F, Guimar\u00e3es V, Rabot S, Alcocer-Gonzalez JM, Gratadoux J-J, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G (2005) A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 175(11):7297\u20137302","journal-title":"J Immunol"},{"issue":"16","key":"3652_CR32","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1016\/j.vaccine.2010.02.005","volume":"28","author":"K Adachi","year":"2010","unstructured":"Adachi K, Kawana K, Yokoyama T, Fujii T, Tomio A, Miura S, Tomio K, Kojima S, Oda K, Sewaki T, Yasugi T, Kozuma S, Taketani Y (2010) Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine 28(16):2810\u20132817","journal-title":"Vaccine"},{"issue":"7","key":"3652_CR33","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2174\/156652409789105525","volume":"9","author":"G Gorfu","year":"2009","unstructured":"Gorfu G, Rivera-Nieves J, Ley K (2009) Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med 9(7):836\u2013850","journal-title":"Curr Mol Med"},{"issue":"8","key":"3652_CR34","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.4161\/hv.29269","volume":"10","author":"M Nizard","year":"2014","unstructured":"Nizard M, Diniz MO, Roussel H, Tran T, Ferreira LC, Badoual C, Tartour E (2014) Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites. Hum Vaccin Immunother 10(8):2175\u20132187","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"3652_CR35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/jmv.25303","volume":"91","author":"AH Mohseni","year":"2019","unstructured":"Mohseni AH, Razavilar V, Keyvani H, Razavi MR, Khavari-Nejad RA (2019) Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL\/6 mice. J Med Virol 91(2):296\u2013307","journal-title":"J Med Virol"},{"issue":"11","key":"3652_CR36","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00262-010-0903-4","volume":"59","author":"T-Y Lee","year":"2010","unstructured":"Lee T-Y, Kim Y-H, Lee K-S, Kim J-K, Lee I-H, Yang J-M, Sung M-H, Park J-S, Poo H (2010) Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL\/6 mice. Cancer Immunol Immunother 59(11):1727\u20131737","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"3652_CR37","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/ijc.22035","volume":"119","author":"H Poo","year":"2006","unstructured":"Poo H, Pyo HM, Lee TY, Yoon SW, Lee JS, Kim CJ, Sung MH, Lee SH (2006) Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57\/BL6 mice. Int J Cancer 119(7):1702\u20131709","journal-title":"Int J Cancer"},{"issue":"2","key":"3652_CR38","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3892\/ol.2013.1743","volume":"7","author":"Y Li","year":"2014","unstructured":"Li Y, Li X, Liu H, Zhuang S, Yang J, Zhang F (2014) Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL\/6 mice. Oncol Lett 7(2):576\u2013582","journal-title":"Oncol Lett"},{"issue":"18","key":"3652_CR39","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1016\/j.vaccine.2006.02.040","volume":"24","author":"R Ramasamy","year":"2006","unstructured":"Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J, Leenhouts K (2006) Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine 24(18):3900\u20133908","journal-title":"Vaccine"},{"issue":"10","key":"3652_CR40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/14760584.2016.1176533","volume":"15","author":"P Vici","year":"2016","unstructured":"Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-Sacc\u00e0 M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, Sanguineti G, Giordano A, De Maria R, Venuti A (2016) Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines 15(10):1327\u20131336","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"3652_CR41","first-page":"1028","volume":"8","author":"B Klencke","year":"2002","unstructured":"Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM (2002) Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8(5):1028\u20131037","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3652_CR42","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1067\/mob.2003.256","volume":"188","author":"EE Sheets","year":"2003","unstructured":"Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI, Cole GA, Crowley-Nowick PA (2003) Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188(4):916\u2013926","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"3652_CR43","first-page":"3676","volume":"8","author":"AM Kaufmann","year":"2002","unstructured":"Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8(12):3676\u20133685","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3652_CR44","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1128\/JVI.73.7.5402-5410.1999","volume":"73","author":"AD Santin","year":"1999","unstructured":"Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ (1999) Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 73(7):5402\u20135410","journal-title":"J Virol"},{"issue":"3","key":"3652_CR45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2007.05.038","volume":"106","author":"LD Roman","year":"2007","unstructured":"Roman LD, Wilczynski S, Muderspach LI, Burnett AF, O'Meara A, Brinkman JA, Kast WM, Facio G, Felix JC, Aldana M, Weber JS (2007) A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 106(3):558\u2013566","journal-title":"Gynecol Oncol"},{"issue":"9","key":"3652_CR46","first-page":"3406","volume":"6","author":"L Muderspach","year":"2000","unstructured":"Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6(9):3406\u20133416","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3652_CR47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrmicro1840","volume":"6","author":"JM Wells","year":"2008","unstructured":"Wells JM, Mercenier A (2008) Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6(5):349\u2013362","journal-title":"Nat Rev Microbiol"},{"issue":"22","key":"3652_CR48","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.vaccine.2008.03.024","volume":"26","author":"KK Yam","year":"2008","unstructured":"Yam KK, Pouliot P, N\u2019diaye MM, Fournier S, Olivier M, Cousineau B (2008) Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis. Vaccine 26(22):2689\u20132699","journal-title":"Vaccine"},{"issue":"2","key":"3652_CR49","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1535-7163.MCT-19-0375","volume":"19","author":"AH Mohseni","year":"2020","unstructured":"Mohseni AH, Taghinezhad SS, Keyvani H (2020) The first clinical use of a recombinant Lactococcus lactis expressing human papillomavirus type 16 E7 oncogene oral vaccine: a phase I safety and immunogenicity trial in healthy women volunteers. Mol Cancer Ther 19(2):717\u2013727","journal-title":"Mol Cancer Ther"},{"key":"3652_CR50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.omtm.2019.08.005","volume":"15","author":"SS Taghinezhad","year":"2019","unstructured":"Taghinezhad SS, Mohseni AH, Keyvani H, Razavi MR (2019) Phase 1 safety and immunogenicity trial of recombinant Lactococcus lactis expressing human papillomavirus type 16 E6 oncoprotein vaccine. Mol Ther Methods Clin Dev 15:40\u201351","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"47","key":"3652_CR51","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1016\/j.vaccine.2014.09.020","volume":"32","author":"K Kawana","year":"2014","unstructured":"Kawana K, Adachi K, Kojima S, Taguchi A, Tomio K, Yamashita A, Nishida H, Nagasaka K, Arimoto T, Yokoyama T, Wada-Hiraike O, Oda K, Sewaki T, Osuga Y, Fujii T (2014) Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. Vaccine 32(47):6233\u20136239","journal-title":"Vaccine"},{"issue":"6","key":"3652_CR52","first-page":"1","volume":"30","author":"YC Park","year":"2019","unstructured":"Park YC, Ouh YT, Sung MH, Park HG, Kim TJ, Cho CH, Park JS, Lee JK (2019) A phase 1\/2a, dose-escalation, safety and preliminary efficacy studyof oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3. J Gynecol Oncol 30(6):1\u201310","journal-title":"J Gynecol Oncol"},{"issue":"9","key":"3652_CR53","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jjco\/hyz095","volume":"49","author":"Y Ikeda","year":"2019","unstructured":"Ikeda Y, Uemura Y, Asai-Sato M, Nakao T, Nakajima T, Iwata T, Akiyama A, Satoh T, Yahata H, Kato K, Maeda D, Aoki D, Kawana K (2019) Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL): the study protocol of a randomized placebo-controlled clinical trial (MILACLE study). Jpn J Clin Oncol 49(9):877\u2013880","journal-title":"Jpn J Clin Oncol"},{"issue":"36","key":"3652_CR54","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1016\/j.vaccine.2012.06.027","volume":"30","author":"A Taguchi","year":"2012","unstructured":"Taguchi A, Kawana K, Yokoyama T, Adachi K, Yamashita A, Tomio K, Kojima S, Oda K, Fujii T, Kozuma S (2012) Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner. Vaccine 30(36):5368\u20135372","journal-title":"Vaccine"},{"issue":"2","key":"3652_CR55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/21645515.2017.1264766","volume":"13","author":"S Massa","year":"2017","unstructured":"Massa S, Paolini F, Curzio G, Cordeiro MN, Illiano E, Demurtas OC, Franconi R, Venuti A (2017) A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines. Hum Vaccin Immunother 13(2):271\u2013282","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"3652_CR56","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AEM.68.2.917-922.2002","volume":"68","author":"L Bermudez-Humaran","year":"2002","unstructured":"Bermudez-Humaran L, Langella P, Miyoshi A, Gruss A, Guerra RT, de Oca-Luna RM, Le Loir Y (2002) Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol 68(2):917\u2013922","journal-title":"Appl Environ Microbiol"},{"issue":"Pt 5","key":"3652_CR57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1099\/jmm.0.05472-0","volume":"53","author":"LG Berm\u00fadez-Humar\u00e1n","year":"2004","unstructured":"Berm\u00fadez-Humar\u00e1n LG, Cortes-Perez NG, Le Loir Y, Alcocer-Gonz\u00e1lez JM, Tamez-Guerra RS, de Oca-Luna RM, Langella P (2004) An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 53(Pt 5):427\u2013433","journal-title":"J Med Microbiol"},{"issue":"1","key":"3652_CR58","doi-asserted-by":"crossref","first-page":"019","DOI":"10.1186\/s12896-019-0499-5","volume":"19","author":"AH Mohseni","year":"2019","unstructured":"Mohseni AH, Taghinezhad SS, Keyvani H, Razavilar V (2019) Extracellular overproduction of E7 oncoprotein of Iranian human papillomavirus type 16 by genetically engineered Lactococcus lactis. BMC Biotechnol 19(1):019\u20130499","journal-title":"BMC Biotechnol"},{"issue":"10","key":"3652_CR59","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2217\/fvl-2018-0026","volume":"13","author":"S Taghinezhad-S","year":"2018","unstructured":"Taghinezhad-S S, Razavilar V, Keyvani H, Razavi MR, Nejadsattari T (2018) Extracellular overproduction of recombinant Iranian HPV-16 E6 oncoprotein in Lactococcus lactis using the NICE system. Future Virol 13(10):697\u2013710. https:\/\/doi.org\/10.2217\/fvl-2018-0026","journal-title":"Future Virol"},{"issue":"3","key":"3652_CR60","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1021\/bp0340077","volume":"19","author":"LG Berm\u00fadez-Humar\u00e1n","year":"2003","unstructured":"Berm\u00fadez-Humar\u00e1n LG, Cortes-Perez NG, Le Loir Y, Gruss A, Rodriguez-Padilla C, Saucedo-Cardenas O, Langella P, Montes de Oca-Luna R (2003) Fusion to a carrier protein and a synthetic propeptide enhances E7 HPV-16 production and secretion in Lactococcus lactis. Biotechnol Prog 19(3):1101\u20131104","journal-title":"Biotechnol Prog"},{"issue":"3","key":"3652_CR61","first-page":"223","volume":"24","author":"E Viti\u00f1i","year":"2000","unstructured":"Viti\u00f1i E, Alvarez S, Medina M, Medici M, de Budeguer MV, Perdig\u00f3n G (2000) Gut mucosal immunostimulation by lactic acid bacteria. Biocell 24(3):223\u2013232","journal-title":"Biocell"},{"issue":"2","key":"3652_CR62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10611860400024219","volume":"13","author":"NG Cortes-Perez","year":"2005","unstructured":"Cortes-Perez NG, Azevedo V, Alcocer-Gonz\u00e1lez JM, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, Gruss A, Langella P, Berm\u00fadez-Humar\u00e1n LG (2005) Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target 13(2):89\u201398","journal-title":"J Drug Target"},{"issue":"1","key":"3652_CR63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0378-1097(03)00778-X","volume":"229","author":"NG Cortes-Perez","year":"2003","unstructured":"Cortes-Perez NG, Berm\u00fadez-Humar\u00e1n LG, Le Loir Y, Rodriguez-Padilla C, Gruss A, Saucedo-C\u00e1rdenas O, Langella P, Montes-de-Oca-Luna R (2003) Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 229(1):37\u201342","journal-title":"FEMS Microbiol Lett"},{"issue":"2","key":"3652_CR64","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12558-015-0369-6","volume":"7","author":"S Kahla","year":"2015","unstructured":"Kahla S, Berm\u00fadez-Humar\u00e1n L, Oueslati R (2015) Construction d\u2019un vecteur d\u2019expression chez Lactococcus lactis bas\u00e9e sur la production d\u2019une prot\u00e9ine ancr\u00e9e de Papillomavirus humain 16 E2\/E7. J Afr Cancer 7(2):104\u2013110","journal-title":"J Afr Cancer"},{"issue":"2","key":"3652_CR65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/0976-500X.130042","volume":"5","author":"JM Cyriac","year":"2014","unstructured":"Cyriac JM, James E (2014) Switch over from intravenous to oral therapy: a concise overview. J Pharmacol Pharmacother 5(2):83","journal-title":"J Pharmacol Pharmacother"},{"key":"3652_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2859-10-S1-S4","volume":"10","author":"LG Berm\u00fadez-Humar\u00e1n","year":"2011","unstructured":"Berm\u00fadez-Humar\u00e1n LG, Kharrat P, Chatel J-M, Langella P (2011) Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Factories 10:1\u20134","journal-title":"Microb Cell Factories"},{"issue":"7","key":"3652_CR67","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1128\/CVI.00050-11","volume":"18","author":"H Lei","year":"2011","unstructured":"Lei H, Sheng Z, Ding Q, Chen J, Wei X, Lam DM, Xu Y (2011) Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B. Clin Vaccine Immunol 18(7):1046\u20131051","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"3652_CR68","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.4049\/jimmunol.1501243","volume":"195","author":"V Chamcha","year":"2015","unstructured":"Chamcha V, Jones A, Quigley BR, Scott JR, Amara RR (2015) Oral immunization with a recombinant Lactococcus lactis-expressing HIV-1 antigen on group A Streptococcus Pilus induces strong mucosal immunity in the gut. J Immunol 195(10):5025\u20135034","journal-title":"J Immunol"},{"issue":"9","key":"3652_CR69","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/fvl-2017-0032","volume":"12","author":"S Taghinezhad-S","year":"2017","unstructured":"Taghinezhad-S S, Razavilar V, Keyvani H, Razavi MR, Nejadsattari T (2017) Codon optimization of Iranian human papillomavirus type 16 E6 oncogene for Lactococcus lactis subsp. cremoris MG1363. Future Virol 12(9):499\u2013511. https:\/\/doi.org\/10.2217\/fvl-2017-0032","journal-title":"Future Virol"},{"key":"3652_CR70","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.micpath.2017.07.039","volume":"110","author":"AH Mohseni","year":"2017","unstructured":"Mohseni AH, Razavilar V, Keyvani H, Razavi MR, Khavari-Nejad RA (2017) Efficient production and optimization of E7 oncoprotein from Iranian human papillomavirus type 16 in Lactococcus lactis using nisin-controlled gene expression (NICE) system. Microb Pathog 110:554\u2013560","journal-title":"Microb Pathog"},{"key":"3652_CR71","first-page":"63","volume":"6","author":"AS Shoja","year":"2008","unstructured":"Shoja AS, Varedi KS, Babaeipour V, Farnoud AM (2008) Recent advances in high cell density cultivation for production of recombinant protein. Iran J Biotechnol 6:63\u201384","journal-title":"Iran J Biotechnol"},{"issue":"24","key":"3652_CR72","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1016\/j.vaccine.2018.05.009","volume":"36","author":"A Komatsu","year":"2018","unstructured":"Komatsu A, Igimi S, Kawana K (2018) Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFN\u03b3-producing cells. Vaccine 36(24):3423\u20133426","journal-title":"Vaccine"},{"issue":"9","key":"3652_CR73","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/vim.2014.0055","volume":"27","author":"BR Rangel-Colmenero","year":"2014","unstructured":"Rangel-Colmenero BR, Gomez-Gutierrez JG, Villatoro-Hern\u00e1ndez J, Zavala-Flores LM, Quisti\u00e1n-Mart\u00ednez D, Rojas-Mart\u00ednez A, Arce-Mendoza AY, Guzm\u00e1n-L\u00f3pez S, Montes-de-Oca-Luna R, Saucedo-C\u00e1rdenas O (2014) Enhancement of Ad-CRT\/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7. Viral immunol 27(9):463\u2013467","journal-title":"Viral immunol"},{"issue":"1","key":"3652_CR74","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2002.20.1.142","volume":"20","author":"JF Toso","year":"2002","unstructured":"Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA (2002) Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20(1):142\u2013152","journal-title":"J Clin Oncol"},{"issue":"30","key":"3652_CR75","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","volume":"27","author":"PC Maciag","year":"2009","unstructured":"Maciag PC, Radulovic S, Rothman J (2009) The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27(30):3975\u20133983","journal-title":"Vaccine"},{"key":"3652_CR76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1475-2859-11-157","volume":"11","author":"E Garc\u00eda-Fruit\u00f3s","year":"2012","unstructured":"Garc\u00eda-Fruit\u00f3s E (2012) Lactic acid bacteria: a promising alternative for recombinant protein production. Microb Cell Factories 11:157\u2013159","journal-title":"Microb Cell Factories"},{"issue":"2","key":"3652_CR77","doi-asserted-by":"crossref","first-page":"e30945","DOI":"10.1371\/journal.pone.0030945","volume":"7","author":"F Hugentobler","year":"2012","unstructured":"Hugentobler F, Yam KK, Gillard J, Mahbuba R, Olivier M, Cousineau B (2012) Immunization against Leishmania major infection using LACK-and IL-12-expressing Lactococcus lactis induces delay in footpad swelling. PLoS ONE 7(2):e30945","journal-title":"PLoS ONE"},{"issue":"4","key":"3652_CR78","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.vaccine.2011.11.098","volume":"30","author":"M Bahey-El-Din","year":"2012","unstructured":"Bahey-El-Din M (2012) Lactococcus lactis-based vaccines from laboratory bench to human use: an overview. Vaccine 30(4):685\u2013690","journal-title":"Vaccine"},{"issue":"9","key":"3652_CR79","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1128\/CVI.00169-08","volume":"15","author":"B del Rio","year":"2008","unstructured":"del Rio B, Dattwyler RJ, Aroso M, Neves V, Meirelles L, Seegers JF, Gomes-Solecki M (2008) Oral immunization with recombinant Lactobacillus plantarum induces a protective immune response in mice with Lyme disease. Clin Vaccine Immunol 15(9):1429\u20131435","journal-title":"Clin Vaccine Immunol"},{"issue":"16","key":"3652_CR80","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0264-410X(96)00117-X","volume":"14","author":"ME Boursnell","year":"1996","unstructured":"Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC (1996) Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14(16):1485\u20131494","journal-title":"Vaccine"},{"issue":"7","key":"3652_CR81","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nbt840","volume":"21","author":"L Steidler","year":"2003","unstructured":"Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E (2003) Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 21(7):785\u2013789","journal-title":"Nat Biotechnol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-020-03652-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-020-03652-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-020-03652-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T23:48:34Z","timestamp":1632613714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-020-03652-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,26]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["3652"],"URL":"https:\/\/doi.org\/10.1007\/s00018-020-03652-2","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,26]]},"assertion":[{"value":"23 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}